Treatment of acute ischemic stroke

New England Journal of Medicine

Volumn 343, Issue 10, 2000, Pages 710-722

  Brott, Thomas ^a   Bogousslavsky, Julien ^b  

^a MAYO CLINIC   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANCROD; HEPARIN;

BRAIN ANGIOGRAPHY; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC THERAPY; NEUROPROTECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOLYTIC THERAPY;

EID: 0034618861     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200009073431007     Document Type: Review

References (143)

1. Stroke trends in the WHO MONICA project
2. Stroke in Europe: Widening gap between East and West
3. The Greater Cincinnati/Northern Kentucky Stroke Study: Preliminary first-ever and total incidence rates of stroke among blacks
4. Activase, alteplase recombinant for acute ischemic stroke: Efficacy supplement
5. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study: A randomized controlled trial
6. Factors determining the therapeutic window for stroke
7. Which targets are relevant for therapy of acute ischemic stroke?
8. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke
9. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours
10. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator
11. Spectrum of pathology responsible for ischemic stroke
12. Lesions, dynamics, and pathogenetic mechanisms responsible for ischemic events in the brain
13. Histopathologic clues to the pathways of neuronal death following ischemia/hypoxia
14. The changing landscape of ischaemic brain injury mechanisms
15. Calcium in ischemic cell death
16. Time course of ADCw changes in ischemic stroke: Beyond the human eye!
17. Mapping the ischaemic penumbra with PET: Implications for acute stroke treatment
18. Current emergency department management of stroke in Houston, Texas
19. Emergency medical services dispatcher identification of stroke and transient ischemic attack
20. Guidelines for the management of patients with acute ischemic stroke: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association
21. The emergency treatment of stroke: The first 6 hours
22. Optimizing intensive care for stroke
23. Frequency and accuracy of prehospital diagnosis of acute stroke
24. Practice guidelines for the use of imaging in transient ischemic attacks and acute stroke: A report of the Stroke Council, American Heart Association
25. Thrombus localization with emergency cerebral CT
26. Acute stroke: Usefulness of early CT findings before thrombolytic therapy
27. Which cardiac diagnosis tests apply in the acute phase of stroke and when are they useful?
28. Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: A cost-effectiveness analysis
29. Intracranial vascular stenosis and occlusion: Diagnostic accuracy of three-dimensional, Fourier transform, time-of-flight MR angiography
30. Yield of transcranial Doppler in acute cerebral ischemia
31. Noninvasive carotid artery testing: A meta-analytic review
32. Role of CT angiography in patient selection for thrombolytic therapy in acute hemispheric stroke
33. Relationship between cerebral blood flow and the development of swelling and life-threatening herniation in acute ischemic stroke
34. tPA-associated reperfusion after acute stroke demonstrated by SPECT
35. Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MILL
36. Intra-arterial rtPA treatment of stroke assessed by diffusion- and perfusion-weighted MILL
37. Evaluation of early reperfusion and i.v. tPA therapy using diffusion- and perfusion-weighted MRI
38. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging
39. Acute hypertension after stroke: The scientific basis for treatment decisions
40. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke: A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association
41. Hypertension and its treatment in the NINDS rt-PA Stroke Trial
42. Tissue plasminogen activator for acute ischemic stroke
43. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke
44. Randomised double-blind placebo·controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
45. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset
46. Improved reliability of the NIH Stroke Scale using video training
47. Effects of tissue plasminogen activator for acute ischemic stroke at one year
48. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke
49. Thrombolytic therapy with streptokinase in acute ischemic stroke
50. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke
51. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group
52. A systems approach to immediate evaluation and management of hyperacute stroke: Experience at eight centers and implications for community practice and patient care
53. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis not a panacea for ischemic stroke
54. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? t-PA the best current option for most patients
55. Generalized efficacy of t-PA for acute stroke: Subgroup analysis of the NINDS t-PA Stroke Trial
56. Identification of lacunar infarcts before thrombolysis in the ECASS I study
57. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience
58. Effectiveness of t-PA in acute ischemic stroke: Outcome relates to appropriateness
59. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study
60. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: A multicenter survey
61. Treating acute stroke patients with intravenous tPA: The OSF Stroke Network experience
62. Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke: Correlations of outcome with clinical and radiological data
63. Intravenous tissue plasminogen activator for acute ischemic stroke: Feasibility, safety, and efficacy in the first year of clinical practice
64. Early intravencus thrombolysis for acute ischemic stroke in a community-based approach
65. Early intravenous thrombolysis with recombinant tissue type plasminogen activator in vertebrobasilar ischemic stroke
66. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke
67. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke: A pilot study
68. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery
69. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease
70. Selective and superselective infusion of urokinase for embolic stroke
71. Local intra-arterial fibrinolytic therapy in patients with stroke: Urokinase versus recombinant tissue plasminogen activator (r-TPA)
72. Safety and efficacy of delayed intraarterial urokinase therapy with mechanical clot disruption for thromboembolic stroke
73. Thrombolytic therapy in acute stroke
74. Fibrinolytic therapy for acute embolic stroke: Intravenous, intracarotid, and intra-arterial local approaches
75. Thrombolyric therapy of acute basilar artery occlusion: Variables affecting recanalization and outcome
76. Intraarterial thrombolysis in vertebrobasilar occlusion
77. Relationship between clot location and outcome after basilar artery thrombolysis
78. Thrombolysis in the vertebrobasilar circulation: The Australian urokinase stroke trial
79. Outcome after local intra-arterial fibrinolysis compared with the natural course of patients with a dense middle cerebral artery on early CT
80. Results of urgent thrombolysis in patients with major stroke and atherothrombotic occlusion of the cervical internal carotid artery
81. Multivariable analysis of predictive factors related to outcome at 6 months after intra-arterial thrombolysis for acute ischemic stroke
82. Intraarterial thrombolysis for treatment of acute stroke: Experience in 26 patients with long-term follow-up
83. Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke
84. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke
85. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke
86. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial
87. The management of thrombosis in antiphospholipid-antibody syndrome
88. Heparin treatment in sinus venous thrombosis
89. Arterial dissections
90. Intraluminal thrombus of the internal Carotid arteries: Angiographic demonstration of resolution with anticoagulant therapy alone
91. The Warfarin-Aspirin Symptomatic Intracranial Disease Study
92. Is there still a role for intravenous hepann in acute stroke? Yes
93. Is there still a role for intravenous heparin in acute stroke? No
94. Heparin in acute stroke with atrial fibrillation: Clinical relevance of very early treatment
95. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke
96. Low-molecular-weight heparin for the treatment of acute ischemic stroke
97. Fraxiparine in ischaemic stroke study (FISS bis)
98. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial
99. Antithrombotic treatment of ischemic stroke among patients with occlusion or severe srenosis of the internal carotid artery: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST)
100. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke
101. IST and CAST: Some answers but more questions
102. Antiplatelet therapy in acute cerebral ischemia
103. Ancrod in the treatment of acute ischemic stroke: A review of clinical data
104. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomized controlled trial
105. Neuroprotection as initial therapy in acute stroke: Third Report of an Ad Hoc Consensus Group Meeting: The European Ad Hoc Consensus Group
106. Clinical trial update: Neuroprotection against acute ischaemic stroke
107. Further evolution toward effective therapy for acute ischemic stroke
108. Medical and neurological complications of ischemic stroke: Experience from the RANTTAS trial
109. Timing for fever-related brain damage in acute ischemic stroke
110. Combating hyperthermia in acute stroke: A significant clinical concern
111. Brain temperature monitoring and modulation in patients with severe MCA infarction
112. Seizures in acute stroke: Predictors and prognostic significance
113. The frequency, causes and timing of death within 30 days of a first stroke: The Oxfordshire Community Stroke Project
114. Swallowing function after stroke: Prognosis and prognostic factors at 6 months
115. Treatment of dysphagia improves nutritional conditions in stroke patients
116. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis
117. A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke
118. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke: A randomized, double-blind study
119. Brain edema after stroke: Clinical syndrome and intracranial pressure
120. Early clinical and radiologic predictors of fatal brain swelling in ischemic stroke
121. Effects of hypertonic saline hydroxyethyl starch solution and mannitol in patients with increased intracranial pressure after stroke
122. The effects of mannitol on cerebral edema after large hemispheric cerebral infarct
123. Treatment of intracranial hypertension
124. German-Austrian Space Occupying Cerebellar Infarction Study (GASCIS): Study design, methods, patient characteristics
125. Early hemicraniectomy in patients with complete middle cerebral artery infarction
126. Strategies for early treatment of acute cerebral infarction
127. Do stroke units save lives?
128. Stroke unit treatment: Long-term effects
129. How do stroke units improve patent outcomes? A collaborative systematic review of the randomized trials
130. Stroke units versus general medical wards, I: Twelve- and eighteen-month survival: A randomized, controlled trial
131. Stroke unit treatment: 10-Year follow-up
132. Stroke units in their natural habitat: Can results of randomized trials be reproduced in routine clinical practice?
133. There's no place like home: An evaluation of early supported discharge for stroke
134. American Heart Association Prevention Conference I.V. Prevention and rehabilitation of stroke: Rehabilitation
135. Rehabilitation of the stroke survivor
136. Clinical determinants of poststroke dementia
137. Stroke and incontinence
138. Outcomes and costs after hip fracture and stroke: A comparison of rehabilitation settings
139. Factors affecting functional outcome after stroke: A critical review of rehabilitation interventions